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Background: The main components of GH/insulin-like growth factor (IGF)-1 axis and Sirtuin 4 (Sirt4), highly
expressed in liver and skeletal musclemitochondria, serve as active regulators of mitochondrial oxidative capac-
ity with opposite functions. In obesity both GH/IGF-1 status and serum Sirt4 levels, likely mirroring its reduced
mitochondrial expression, might be altered.
Objective: To evaluate the association between circulating levels of Sirt4, body composition, metabolic parame-
ters and cardio-metabolic risk proﬁle in obese patients according to their different GH/IGF-1 status.
Design: Cross-sectional study with measurement of serum Sirt4, GH after GH releasing hormone (GHRH) +
Arginine test, IGF-1 and assessment of body composition, glucose and lipid metabolism in 50 class II–III obese
subjects (BMI 35.6 to 62.1 kg/m2) and 15 normal weight subjects. Low GH secretion and IGF-1 were deﬁned
using pre-determined cutoff-points. The Homeostatic Metabolic Assessment of insulin resistance index and
Visceral adiposity index were also calculated. The association of Sirt4 with peak stimulated GH and IGF-1,
body composition, metabolic parameters and cardio-metabolic risk proﬁle was assessed.
Results: Serum Sirt4 was inversely related to anthropometric andmetabolic parameters and positively related to
peak GH and IGF-1. After adjusting for peak GH and IGF-1, the relationships between Sirt4 and BMI became not
signiﬁcant. At multiple regression analysis IGF-1 (p b 0.001) was the independent predictor for Sirt4.
Conclusion: There was a close relationship between low IGF-1 and low serum Sirt4. This observation suggested
that in obese patients, low GH/IGF-1 status was likely associated with a major compensatory decrease in circu-
lating levels of Sirt4 to oppose to its negative regulator effect on mitochondrial oxidative capacity.© 2014 Elsevier Ltd. All rights reserved.1. Introduction
Apart from their effects on linear growth before puberty, growth
hormone (GH) and insulin-like growth factor (IGF)-1, themain compo-
nents of the GH axis, have deﬁned anabolic functions and act as key reg-
ulators of energy metabolism in adulthood [1]. Actually, the interaction
between the GH axis and body weight can be viewed as part of theGT contributed to drafting the
data. CDS, LB, and CF performed
FC critically revised the text.
a Clinica e Chirurgia, Unità di
Pansini, 5, 80131 Naples, Italy.overall regulation of body composition across the feeding/fasting
cycle, being adipose tissue and skeletal muscle as major targets of the
action of the GH/IGF-1 axis. Of interest, GH and IGF-1 receptors
expressed on skeletal muscle have been reported to regulate basal skel-
etal muscle lipid oxidation [2] and to promote mitochondrial oxidative
capacity [3,4]. Albeit mainly reversible after calorie restriction and
sustained weight loss [5], the low GH/IGF-1 status in obese individuals
might be one of the factors accounting for heterogeneity in metabolic
phenotype among equally obese subjects, as this subset of obese sub-
jects presented with higher prevalence of cardio-metabolic risk factors
[6] and worse body composition compared with obese individuals
with a normal GH/IGF-1 axis [7]. In particular, we previously reported
that up to 1/3 of severely obese patients exhibited a low GH/IGF-I status
associated with signiﬁcantly higher fat mass and waist circumference
[8] or metabolic syndrome prevalence [9].
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production to metabolic demand [10]. Sirtuin 1 and Sirtuin 4 (Sirt4)
are involved in insulin secretion [11] and in maintaining the balance
of glucose/lipid metabolism in type 2 diabetes mellitus (T2DM) [12].
Sirt4, ubiquitously expressed in many organs including skeletal muscle
and the liver, functionswithin themitochondria as negative regulator of
mitochondrial oxidative capacity [13]. Evidence now indicates that the
increased oxidative stress, due to excess visceral obesity, as the main
source of cytokines and adipokines [14], is one of the factors involved
inmitochondrial dysfunction [15]. Very recently, we evidenced that cir-
culating levels of Sirt4, likely mirroring its reduced mitochondrial ex-
pression, are low in obese patients, likely as an attempt to preserve in
obesity the mitochondrial oxidative capacity, and are associated with
cardiovascular risk factors [16]. Aside from Sirt4, also GH has been re-
ported to actively regulate mitochondrial oxidative capacity. Actually,
both low GH/IGF-1 status and low serum Sirt4 levels could occur con-
comitantly in obesity. However, the possible relationship between
Sirt4 and anthropometric and metabolic parameters among obese sub-
jects according to GH/IGF-1 status has not been investigated formerly.
The aim of the present study was to evaluate the association be-
tween circulating levels of Sirt4, body composition, metabolic parame-
ters and cardio-metabolic risk proﬁle in obese patients according to
their different GH/IFG-1 status.
2. Materials and methods
2.1. Study design and population
In order to calculate the minimum required sample the means of
Sirt4 were evaluated. Out of the 97 consecutivemorbidly obese subjects
referred to the out-patient Endocrinology Unit, from January 2013 to
December 2013, 50 obese subjects were enrolled in this cross-
sectional study. All subjects underwent complete medical history and
clinical examination and the selection was based on GH/IGF-1 status
as assessed during their screening procedure for bariatric surgery by
evaluating peak GH after the GHRH + Arginine (ARG) stimulation test
and IGF-1 circulating levels as indicators of GH sufﬁciency. Subjects
were eligible if they presented with established obesity (at least three
years), and were on a balanced low calorie, low fat (25% of calories)
diet (lasting at least three months). Systolic blood pressure (SBP) and
diastolic blood pressure (DBP) were measured with a previously cali-
bratedmercury sphygmomanometer, and themean value of threemea-
surementswas calculated. Exclusion criteriawere: 1) presence of T2DM
[17]; 2) presence of liver or renal failure, cancer, and acute or chronic
inﬂammatory diseases based on a complete medical examination
and laboratory investigations; 3) presence of additional pituitary hor-
mone deﬁciency, speciﬁcally: a) diabetes insipidus was ruled out by
normal urine volume (b2.5–3 l/24 h) with normal urine osmolality
(N300 mmol/kg); b) normal adrenal function was demonstrated by
early-morning (at 9.00 am) cortisol concentrations more than 80 μg/l
and 24 hour urinary free cortisol levels N30 μg/24 h; c) absence of sec-
ondary hypothyroidism was demonstrated by normal FT4 (N8 ng/l)
concentrations with normal TSH levels; d) the absence of secondary
hypogonadism was demonstrated by: i) in premenopausal women
with normal menstrual patterns (i.e. at least 10 menstrual periods in
the previous year, the last less than 60 days before the 1st examination),
normal estradiol levels (N20 pg/ml) with normal FSH and LH levels; ii)
inmen by normal testosterone levels (N3 μg/l) with normal FSH and LH
levels; 4) subjects onweight lossmedications, or hormonalmedications
including estrogen, testosterone, glucocorticoids, anabolic steroids,
GHRH, GH, IGF-1, hormonal contraception, or other drugs (i.e., aspirin,
metformin, statins and ﬁbrates) known to possibly alter laboratory
data, were excluded. Fifteen lean, apparently healthy, subjects
(screened for the entire laboratory panel and instrumental parameters
used for the obese individuals) were chosen as controls to avoid any
confounding factor with circulating Sirt4 levels. The study wasconducted without support from the pharmaceutical industry, after
approval by the institutional review board of the University of Naples,
Italy (n. 5/14). As control group 15 Caucasian normal weight subjects
(5 males, mean age 33.4 ± 7.8 years) were chosen between volunteers
and employees of our Institution, with comparable education, income,
marital status, smoking habits, or participation in physical activity. The
purpose of the protocol was explained to the patients and an informed
written consent was obtained from each patient at the beginning of
the study.
2.2. Assay methods
Samples were collected in themorning between 8 and 10 a.m., after
an overnight fast of at least 8 h and stored at−80 °C until being proc-
essed. All biochemical analyses including fasting plasma glucose, total
cholesterol, HDL cholesterol, LDL cholesterol, triglycerides and transam-
inases were performed with a Roche Modular Analytics System in the
Central Biochemistry Laboratory of our Institution. LDL cholesterol and
HDL cholesterol were determined by a direct method (homogeneous
enzymatic assay for the direct quantitative determination of LDL and
HDL cholesterol). Glycated hemoglobin (HbA1C) was measured by
HPLC. In premenopausal women hormonal investigations were per-
formed during the early follicular phase, 5–7 days after spontaneous
menses. Serum GH levels were measured by immunoradiometric
assay (IRMA) using commercially available kits (HGH-CTK-IRMA,
Sorin, Saluggia, Italy). The sensitivity of the assay was 0.2 μg/l. The
intra- and interassay coefﬁcients of variations (CVs) were 4.5 and
7.9%, respectively. Plasma IGF-1 was measured by IRMA after ethanol
extraction. The sensitivity of the assay was 0.8 μg/l. According to our
population reference values [18], the normal IGF-1 range in 20–40,
41–60, and over 60-year-old subjects was 110–494, 100–300, and 78–
260 μg/l, respectively. The intra-assay CVs were 3.4, 3.0, and 1.5% for
low, medium, and high points on the standard curve, respectively. The
inter-assay CVswere 8.2, 1.5, and 3.7% for low,medium, and high points
on the standard curve, respectively. Total insulin levels were measured
by a solid-phase chemiluminescent enzyme immunoassay using a com-
mercially available kit (Immunolite Diagnostic Products Co, Los Angeles,
CA). The intra-assay coefﬁcients (CV) of variationswere less than 5 · 5%
for insulin assay. Insulin resistancewas determined by the Homeostasis
model assessment of insulin resistance (HoMA-IR), whichwas assessed
by the formula: fasting insulin (μU/ml) × fasting glucose (mg/dl) ∕ 405,
according to Matthews et al. [19]. Visceral adiposity index (VAI) score
was calculated using the gender-speciﬁc reported formula [20] and was
(waist circumference ∕ 39.68 + (1.88 × BMI)) ×(triglycerides ∕ 1.03) ×
(1.31 ∕ HDL cholesterol).
2.3. Assessment of GH secretion
TheGHRH+ARG test was performed after an overnight fast accord-
ing to Ghigo et al. [21]: ARG (arginine hydrochloride, Salf, Bergamo,
Italy) was administered at a dose of 0.5 g/kg, up to a maximal dose of
30 g, slowly infused from time 0 to 30 min, while GHRH (1-29, Geref,
Serono, Rome, Italy) was given at a dose of 1 μg/kg as i.v. bolus at time
0. Blood samples were taken every 15 min from−15 up to 90 min. A
cut-off value of ≤4.2 μg/l was used for peak stimulated GH, based on
Corneli et al. [22]. IGF-1 z score or standard deviation score (SDS) for
age and gender was also calculated according to our population
reference values [18] and used for further analysis. For the purpose of
this study, IGF-1 levels were classiﬁed as “normal” when higher than
−2.0 SD and “deﬁcient”when lower than−2.0 SD [23].
2.4. Determination of circulating Sirt4 levels
The kit for in vitro quantitative measurement of Sirt4 in human tis-
sue homogenates and other biological ﬂuids, based on a sandwich en-
zyme immunoassay, was provided by Uscn Life Science & Technology
Table 1
Clinical and metabolic characteristics.
Number of patients 50
Demographics
Gender (F/M) 33/17
Age (years) 37.1 ± 9.7
Body composition
BMI (kg/m2) 46.4 ± 6.0
VAI 5.5 ± 3.5
EBW (kg) 70.3 ± 19.8
Waist circumference (cm) 148.6 ± 14.9 (M)
134.3 ± 18.9 (F)
Fat mass (kg) 58.9 ± 14.1 (M)
61.2 ± 18.1 (F)
Fat mass (%) 40.1 ± 5.7 (M)
48.3 ± 6.9 (F)
Free fat mass (kg) 81.6 ± 21.4 (M)
63.3 ± 8.3 (F)
Free fat mass (%) 59.9 ± 5.7 (M)
55.7 ± 6.9 (F)
Metabolic parameters
Fasting plasma glucose (mg/dl) 97.5 ± 13.7
Fasting insulin (μU/ml) 21.2 ± 9.5
HoMA-IR 5.2 ± 2.6
HbA1C 5.9 ± 0.4
Total cholesterol (mg/dl) 194.6 ± 36.6
HDL cholesterol (mg/dl) 45.9 ± 11.8 (M)
46.1 ± 11.0 (F)
LDL cholesterol (mg/dl) 116.4 ± 31.2
Triglycerides (mg/dl) 149.8 ± 88.1
AST (U/l) 23 (10–109)
ALT (U/l) 35 (9–202)
γGT (U/l) 30 (11–242)
SBP (mm Hg) 131.7 ± 14.1
DBP (mm Hg) 83.5 ± 10.1
GH status
Peak GH (ng/ml) 2.6 (0.05–10)
Peak GH b 4.2 ng/ml 30 (60%)
IGF-1 (ng/ml) 138.0 ± 38.9
IGF-1 SD b 2.5 29 (58%)
Low Peak GH and IGF-1 SDS 31 (62%)
Values are mean ± SD except for liver function tests, and peak GH which are reported as
median (range). Peak GH after GH releasing hormone (GHRH) + Arginine test was per-
formed according to Ghigo et al. [21]. IGF-1 z score or standard deviation score (SDS) for
age and gender was also calculated according to our population reference values [18].
Low GH secretion [22] and low IGF-1 levels [23] were deﬁned using pre-determined cut-
off-points. HoMA-IR and VAI were also calculated, according to Matthews et al. [19] and
Amato et al. [20], respectively.
BMI, Body Mass Index; VAI, Visceral adiposity index; EBW, Excess BodyWeight; HoMA-IR,
HoMA-IR, Homeostasis model assessment of insulin resistance; HbA1C, glycated
hemoglobin; AST, Alanine Transaminase; ALT, Aspartate Transaminase; γGT, Gamma-
glutamyltransferase; SBP, systolic blood pressure; DPB, diastolic blood pressure; GH,
growth hormone; IGF-1, insulin-like growth factor-1; IGF-1 SDS, IGF-1 z score or standard
deviation score.
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detection range was 0.156–10 ng/ml, as reported elsewhere [16].
Brieﬂy, the standard curve concentrations used for the ELISA were
10 ng/ml, 5 ng/ml, 2.5 ng/ml, 1.25 ng/ml, 0.625 ng/ml, 0.312 ng/ml,
and 0.156 ng/ml. The sensitivity of this assay was deﬁned as the lowest
protein concentration that could be differentiated from zero. It was de-
termined by adding two standard deviations to themean optical density
value of twenty zero standard replicates and calculating the corre-
sponding concentration. The minimum detectable dose of human Sirt4
was less than 0.051ng/ml. No signiﬁcant cross-reactivity or interference
between human Sirt4 and other sirtuins was observed, according to
manufacturer data. Intra-assay precision was determined as follows:
three samples with low, middle and high level human Sirt4 were tested
20 times on one plate. The inter-assay precision was weighed testing
three samples with low, middle and high level human Sirt4 on 3 differ-
ent plates, 8 replicates in each plate. The coefﬁcient of variation, calcu-
lated by SD/mean × 100 for the intra-assay and inter-assay was b10%
and b12%, respectively.
2.5. Anthropometric measurements
All anthropometric measurements were taken with subjects wear-
ing only light clothes andwithout shoes. In eachmen,weight and height
were measured to calculate the BMI [weight (kg) divided by height
squared (m2), kg/m2]. Height was measured to the nearest cm using a
wall-mounted stadiometer. Bodyweightwas determined to the nearest
50 g using a calibrated balance beam scale. The degree of obesity was
established on the basis of BMI cut-off points of 30–34.9 (class I obesity),
35–39.9 (class II obesity) and≥40 kg/m2 (class III obesity), respectively.
Excess Body Weight (EBW) was calculated as actual weight − ideal
weight. Visceral obesity was identiﬁed by measuring waist circumfer-
ence using a ﬂexible steel tape measure at the natural indentation or
at a level midway between the iliac crest and the lower edge of the rib
cage if no natural indentation was visible. Body composition was per-
formed in each patient with bioimpedance analysis (single-frequency
50 kHz BIA 101 RJL, Akern Bioresearch, Firenze).
2.6. Statistical analysis
Theminimum required total samplewas calculated using the pooled
standard deviation with the level test 0.05 and power 90% of Sirt4 in
obese patients and controls. Study variables are shown asmean± stan-
dard deviation (SD) or asmedian plus range according to variables' dis-
tribution analyzed by the Kolmogorov–Smirnov test. To correct for
skewed distributions, Sirt4 and peak GH values were logarithmically
transformed and back-transformed for presentation in tables and ﬁg-
ures. Differences in serum Sirt4 levels between obese subjects and nor-
mal weight controls were analyzed by Mann–Whitney U test. Pearson's
correlation coefﬁcients and partial correlation coefﬁcients were used to
assess the relationship between serum concentrations of Sirt4, body
composition,metabolic parameters, peak GH and IGF-1 levels. To assess
the independent effect of a quantitative variable on the prediction of an-
other one, the linear regression analysis (least squares) was used, eval-
uating the coefﬁcient with its standard error, 95% conﬁdence intervals
(CI), the t (t-stat), and p values. A t-stat greater than 1.96 with a signif-
icance less than 0.05 indicates that the independent variable is a signif-
icant predictor of the dependent variable within and beyond the
sample. A multiple linear regression analysis model (stepwise method)
was used to estimate the predictive value of peak GH, IGF-1 SDS and
waist circumference, expressed asR2, Beta (β) and twith Sirt4 as depen-
dent variable. In this analysis,we entered only those variables that had a
p-value b0.05 in the univariate analysis (partial correlation). To avoid
multicollinearity, variables with a variance inﬂation factor (VIP) N10
were excluded. Data were stored and analyzed using the MedCalc®
package (Version 13.0 — © 1993–2014 MedCalc Software bvba —
MedCalc Software, Mariakerke, Belgium).3. Results
When calculating theminimum required sample, evaluating the dif-
ference of mean of Sirt4 with a type I error of 0.10 and a type of II (β)
error of 0.05, the resulting size of the groups was 48 and 15, respective-
ly. Of the initial 97 participants, eight T2DM patients on treatment with
metformin and nine patients on lipid lowering drugs (two on statins,
three on ﬁbrates and four on statin–ﬁbrate combination for mixed hy-
perlipidemia) were excluded. Eleven obese subjects were excluded be-
cause they had undergone steroid therapy (ﬁve for inﬂammatory bowel
disease, three for Chronic Obstructive Pulmonary Disease, two for se-
vere psoriasis, one for rheumatoid arthritis). Three patients with Ob-
structive Sleep Apnea Syndrome, seven males with obesity-related
hypogonadism, and nine obese women taking contraceptives were
also excluded. Characteristics of the 50 obese subjects participating in
the study are summarized in Table 1. All presented with class II–III obe-
sity, with BMIs ranging from 35.6 to 62.1 kg/m2. Eleven patients were
Table 2
Correlation coefﬁcients between Sirtuin 4, anthropometric and metabolic variables, GH
and IGF-1.
Bivariate
correlation
Partial
correlationa
Partial
correlationb
BMI −0.487 −0.368 −0.263
b0.001 0.010 0.071
Waist circumference −0.552 −0.494 −0.354
b0.001 b0.001 0.011
Fat mass −0.330 −0.164 −0.229
0.019 0.260 0.118
EBW −0.512 −0.409 −0.274
b0.001 0.004 0.060
VAI −0.354 −0.268 −0.227
0.012 0.062 0.121
Insulin −0.351 −0.054
0.013 0.713
Triglycerides −0.311 −0.242 −0.240
0.028 0.094 0.100
Total cholesterol −0.285 −0.234 −0.221
0.045 0.106 0.131
LDL cholesterol −0.441 −0.298 −0.226
0.001 0.038 0.122
DBP −0.312 −0.187 −0.008
0.027 0.193 0.550
Peak GH 0.445 0.306
0.001 0.032
IGF-1 SDS 0.548 0.461
b0.001 0.001
Simple correlation coefﬁcients are reported in ﬁrst column, while partial correlation coef-
ﬁcients obtained after adjusting for fasting insulin or peak GH and IGF-1, respectively, are
reported in the second and third columns. To correct for skewed distributions, Sirt4 and
peak GH values were logarithmically transformed and back-transformed for presentation
in the table. Signiﬁcant correlations and their p values have been reported as bold-faced
and italicized data, respectively.
BMI, Body Mass Index; VAI, Visceral adiposity index; EBW, Excess BodyWeight; DPB, dia-
stolic blood pressure;GH, growth hormone; IGF-1, insulin-like growth factor-1; IGF-1 SDS,
IGF-1 z score or standard deviation score.
a Correlation coefﬁcients were adjusted for insulin.
b Correlation coefﬁcients were adjusted for GH status (peak GH and IGF-1 SDS).
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levels greater than 110 mg/dl but less than 126 mg/dl. Serum Sirt4 in
obese subjects were signiﬁcantly lower than in normal weight subjects:
0.38 (0.05–10.16) ng/ml vs 6 (1.18–20.00) ng/ml (p = 0.001; Fig. 1),
without any signiﬁcant gender differences (p = 0.556).
Assuming 4.2 ng/ml to be the peak GH cut-off point established for
the GHRH+ ARG test in obese individuals cut-off points for diagnosing
GHD and IGF-1 SDS≤−2.0 for diagnosing IGF-1 deﬁciency, more than
one half of obese subjects in this series presented with low peak GH or
low IGF-1 levels, with a 60% concordance rate of low peak GH and low
IGF-1. When obese subjects were grouped according to their GH/IGF-1
status, obese subjects with low peak GH and/or low IGF-1 levels
(31 subjects), presented with lower Sirt4 (0.29 (0.05–3.3) vs 2.5
(0.08–10.16)), and higher values of BMI (48.6 ± 6.1 vs 42.9 ± 4.0;
p = 0.001), waist circumference (145.8 ± 15.8 vs 129.8 ± 18.7;
p = 0.002), VAI (6.4 ± 4.0 vs 3.9 ± 1.9; p = 0.011), and HoMA-IR
(6.1 ± 2.4 vs 3.6 ± 2.1; p b 0.001) than obese subjects (19 subjects)
with normal GH/IGF-1 status, albeit there were no age differences be-
tween the two groups (36.2 ± 9.1 vs 38.4 ± 10.7; p = 0.441).
3.1. Correlation studies
Table 2 shows the correlations between Sirt4 and the study vari-
ables. These data demonstrate the presence of signiﬁcant associations
between serum Sirt4 and BMI, waist circumference, fat mass, EBW,
VAI, insulin, triglycerides, total cholesterol, LDL cholesterol, DBP, peak
GH, and IGF-1 SDS. Otherwise, no signiﬁcant relationship was detected
between Sirt4 and age (p= 0.140), fasting glucose (p= 0.570), HoMA-
IR (p = 0.083), HDL cholesterol (p = 0.152), liver function tests (AST:
p = 0.563; ALT: p = 0.487; γGT: p = 0.065), and SBP (p = 0.570).
Because of the presence in our series of two conditions known
or suspected to affect Sirt4 levels, such as insulin levels and low GH/
IGF-1 status, respectively, the correlation coefﬁcients were adjusted
for insulin, peak GH or IGF-1 levels. When this was done, in the ﬁrst
case Sirt4 still remained signiﬁcantly correlated with BMI, the majority
of anthropometric variables, peak GH and IGF-1; whereas after
adjusting for peak GH and IGF-1, the relationships between Sirt4 and
BMI became not signiﬁcant, and only waist circumference and VAI
maintained their signiﬁcant association with Sirt4 (Table 2). Fig. 2 (a,
b, c, d) shows the signiﬁcant prediction of anthropometric variables,
peak GH or IGF-1 levels as independent variables on serum Sirt4. The
prediction of lower Sirt4 levels by major severity of BMI, higher waist
circumference and lower peak GH and IGF-1 was well documented.
Consequently, we performed a multiple regression analysis to deter-
mine between anthropometric variables, peak GH or IGF-1 levels
the major predictor of Sirt4. The data reported in Table 3 show that
when waist circumference, peak GH and IGF-1 were forced into the
model together, being BMI, VAI and EBW not present due to theirp< 0.001
Fig. 1. Behavior of serum circulating Sirtuin 4 (ng/ml) in normal weight controls and the
study population of class II–III obese individuals. To correct for skewed distributions,
Sirtuin 4 values were logarithmically transformed and back-transformed for presentation
in the ﬁgure. Sirtuin 4, Sirt4.multicollinearity with waist circumference, IGF-1 (p b 0.001) was
independently related to Sirt4, while waist circumference and peak
GH lost their independent predictive power, highlighting the close rela-
tionship between low IGF-1 and low serum Sirt4 (for the entire model,
R2 = 0.407).
4. Discussion
Our present results indicate that low serumSirt4 levels in obese sub-
jects are correlated to low peak GH and low IGF-1 levels. In addition,
serum Sirt4 shows a negative correlation with anthropometric vari-
ables, such as BMI andwaist circumference, with cardiovascular risk fac-
tors, i.e., insulin, triglycerides, total cholesterol, LDL cholesterol, DBP and
VAI, recently considered a reliable indicator of cardio-metabolic risk
[20].
This observation conﬁrms and extends our previous ﬁnding that cir-
culating levels of Sirt4 are low in obese subjects with ectopic fat storage
in the liver and skeletal muscle and are associated with increased car-
diovascular risk factors [16]. Although there is a limitation in its inter-
pretation due to the small size of this cohort, we found in the present
study that the subset of obese subjects with low peak GH and low IGF-
1 levels have lower serum Sirt4 levels and higher BMI, waist circumfer-
ence and VAI compared with their counterpart with normal GH/IGF-1
status. Thus, the question arises as towhether the low serumSirt4 levels
in the subset of obese subjects with low GH/IGF-1 status are only the
consequence of their greater severity of obesity. Indeed, after adjusting
the correlations between Sirt4 and anthropometric variables for peak
GH and IGF-1, the relationship between Sirt4 and BMI became not sig-
niﬁcant. This preliminary result lets us hypothesize that GH/IGF-1 status
was more powerful in inﬂuencing the Sirt4 levels. In addition, at the
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used in our series of obese subjects, peak GH and IGF-1, IGF-1 remained
the major predictor for Sirt4.
In the clinical setting of the heterogeneity of obesity phenotype, it is
currently accepted that the GH/IGF-1 status might play a pivotal role in
contributing to determine different body compositions and cardio-
metabolic risk proﬁles among equally obese subjects [6–9]. Very recent-
ly, Stanley [24] reported that obese subjects presenting with reduction
of either IGF-1 or peak GH had higher carotid intima-media thickness,
a functional and structural marker of early atherosclerosis, compared
to obese subjects with both normal peak GH and IGF-1 levels. GH andTable 3
Multiple regression analysis model.
R2 β t p
IGF-1 SD 0.407 0.637 5.730 b0.001
Variables excluded
Waist circumference −0.220 −1.827 −0.074
Fasting insulin 0.027 −0.214 0.831
Peak GH 0.149 1.207 0.233
The multiple regression analysis (stepwise method) was used to estimate the predictive
value of peak GH, IGF-1 SDS and waist circumference with Sirt4 as dependent variable.
In this analysis, we entered only those variables that had a p-value b0.05 in the univariate
analysis (partial correlation). The multiple regression analysis shows that IGF-1 was inde-
pendently related to Sirt4, while waist circumference and peak GH lost their independent
predictive power, highlighting the close relationship between low IGF-1 and low serum
Sirt4.
Sirtuin 4, Sirt4;GH, growth hormone; IGF-1, insulin-like growth factor-1; IGF-1 SDS, IGF-1 z
score or standard deviation score.IGF-1, through their receptors expressed on skeletal muscle, have
been reported to actively up-regulate mitochondrial oxidative capacity
[3,4]. Thus, the low GH/IGF-1 status in obese individuals might repre-
sent the major contributor to reducing the β-oxidation as an example
of the maladaptive endocrine changes operating in obesity.
In addition, a role for Sirt4 in regulating fatmetabolism by increasing
β-oxidation of fatty acid has been well described, due to its ability to
deacetylate malonyl-CoA-decarboxylase. In particular, Sirt4 inhibition
increases fat oxidative capacity in the liver and mitochondrial function
in muscle, with possible therapeutic beneﬁts for diseases associated
with ectopic lipid storage such as T2DM [25]. Moreover, in Sirt4 knock-
out mice, Sirt4 deﬁciency leads to a protection from high fat diet-
induced obesity linked to the increased β-oxidation [26]. Finally, fasting
and/or calorie restriction are reported to be associatedwith reduced ex-
pression of hepatic Sirt4 [25]. Thus, the GH/IGF-1 axis and Sirt4 serve as
active regulators of mitochondrial oxidative capacity with opposite
functions. A number of recent studies have indicated the possible impli-
cation of impaired skeletal muscle mitochondrial oxidative phosphory-
lation as the underlying etiologic element of a variety of disorders
including obesity, insulin resistance, and diabetes [27,28], although
the causative or compensatory effect of mitochondrial oxidative capac-
ity remained to be elucidated [29].
The precise pathophysiological mechanisms linking low serum Sirt4
with low GH/IGF-1 status were not thoroughly analyzed in this study as
the comparative tissue evaluation of Sirt4 expression or activity in cell
cultures was lacking. However, for ethical issues we preferred to avoid
performing muscle or liver biopsies as preliminary approach in this
study. Nevertheless, the association between low Sirt4, low peak GH
33S. Savastano et al. / Growth Hormone & IGF Research 25 (2015) 28–33and low IGF-1 levels in the clinical setting of obesity and cardiovascular
risk could have an intriguing hypothesis. In our previous work we sug-
gested that low serum Sirt4, likely mirroring a reduced mitochondrial
expression, represented an attempt to preserve in obesity the
mitochondrial oxidative capacity, providing beneﬁts for the associated
ectopic lipid storage excess. In the present study, vice versa, it is tempt-
ing to speculate that in obese patients, low GH/IGF-1 status, most
frequently characterized by a higher prevalence of cardio-metabolic
risk factors, is likely associated with a major compensatory decrease in
circulating levels of Sirt4 to oppose to its negative regulator effect onmi-
tochondrial oxidative capacity. A clinical implication is that the concom-
itant evaluation of circulating levels of Sirt4 in addition to other classic
risk factors in obese individuals could help to better characterize the
subset of subjects with low GH/IGF-1 status, higher cardio-metabolic
risk and lower effective adaptation to calorie restriction.
Aside from obesity, glucose metabolism is another factor which
might inﬂuence Sirt4. Evidence has been provided that mRNA expres-
sion of Sirt4 in granulocytes and monocytes of T2DM patients was
lower compared with healthy individuals, with a negative correlation
between Sirt4 and fasting plasma glucose [12]. However, after adjusting
for insulin, Sirt4 still remained signiﬁcantly correlated with BMI, peak
GH and IGF-1 levels.
We are aware that there are some limitations in our study. First, our
sample size is small. Second, the cross-sectional design of the study pre-
cludes the possibility of establishing the direction of causality between
low Sirt4 with low GH/IGF-1 status in obesity. Third, we do not provide
experimental data on muscle biopsy sample to conﬁrm the link be-
tween Sirt4 and GH/IGF-1 status; thus, our hypothesis of a compensa-
tive reduction of serum Sirt4 as the consequence of the low GH/IGF-1
status remains largely speculative.
In conclusion, there was a close relationship between low serum
Sirt4 and low IGF-1, likely representing a compensatory mechanism to
oppose to the negative regulator effect exerted by Sirt4 onmitochondri-
al oxidative capacity. Further studies on larger series of obese subjects
will help conﬁrm if the relationship between Sirt4 and GH/IGF-1 status
is only a matter of an adaptive mechanism to the obesity-related re-
duced mitochondrial oxidative capacity or is a dependent effect of the
perturbations along the GH/IGF-1 axis.Conﬂict of interest
Wewish to conﬁrm that there are no known conﬂicts of interest as-
sociatedwith this publication and there has beenno signiﬁcantﬁnancial
support for this work that could have inﬂuenced its outcome.References
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